Toujeo, Perjeta Biosimilars On Biocon-Mylan Menu But Humira Version Iffy

 
• By Anju Ghangurde

Biocon is building on its alliance with Mylan and the partners are adding biosimilar programs for insulin glargine 300 units/mL and pertuzumab to their pipeline. But there's little clarity on the duo's ongoing program for biosimilar adalimumab in the backdrop of Mylan's recent deal with Fujifilm Kyowa Kirin Biologics for its product.

Success ladder leading to cloud and many short ones. Business, goal, competition, unique, progress, challenge, hope and leadership concept. EPS 8 vector illustration, no transparency
BIOCON AND MYLAN ARE ADDING PRODUCTS TO THEIR ALLIANCE

More from Deals

More from Business